Wedmont Private Capital Purchases 507 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Wedmont Private Capital increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 11.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,972 shares of the specialty pharmaceutical company’s stock after purchasing an additional 507 shares during the quarter. Wedmont Private Capital’s holdings in Jazz Pharmaceuticals were worth $540,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of JAZZ. V Square Quantitative Management LLC grew its stake in Jazz Pharmaceuticals by 63.9% in the fourth quarter. V Square Quantitative Management LLC now owns 680 shares of the specialty pharmaceutical company’s stock worth $84,000 after purchasing an additional 265 shares in the last quarter. Virtu Financial LLC boosted its position in Jazz Pharmaceuticals by 104.6% during the 4th quarter. Virtu Financial LLC now owns 8,877 shares of the specialty pharmaceutical company’s stock valued at $1,092,000 after acquiring an additional 4,538 shares in the last quarter. HighPoint Advisor Group LLC bought a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $240,000. Newbridge Financial Services Group Inc. boosted its position in Jazz Pharmaceuticals by 254.5% during the 4th quarter. Newbridge Financial Services Group Inc. now owns 468 shares of the specialty pharmaceutical company’s stock valued at $58,000 after acquiring an additional 336 shares in the last quarter. Finally, Centre Asset Management LLC bought a new stake in Jazz Pharmaceuticals during the 1st quarter valued at $8,475,000. Institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $108.80 on Friday. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $137.38. The business has a 50-day moving average price of $110.60 and a 200 day moving average price of $109.96. The firm has a market cap of $6.86 billion, a PE ratio of 22.43, a P/E/G ratio of 1.34 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. Sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on JAZZ. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Robert W. Baird dropped their target price on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. Morgan Stanley dropped their target price on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Friday, July 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $205.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, September 10th. Finally, Piper Sandler dropped their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.14.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.